Last update 01 Nov 2024

TNFAIP3 x HLA-E x TXNIP x PDL1 x B2M x MANF

Basic Info

Related Targets
TNFAIP3HLA-ETXNIP[+3]

Related

1
Drugs associated with TNFAIP3 x HLA-E x TXNIP x PDL1 x B2M x MANF
VCTX-211
Target
B2M x HLA-E x MANF x PDL1 x TNFAIP3 x TXNIP
Mechanism
B2M inhibitors [+6]
Active Org.
CRISPR Therapeutics AGCRISPR Therapeutics AG
Originator Org.
ViaCyte, Inc.ViaCyte, Inc. [+1]
Active Indication
Diabetes Mellitus, Type 1
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with TNFAIP3 x HLA-E x TXNIP x PDL1 x B2M x MANF
NCT05565248 / RecruitingPhase 1/2
An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)
100 Clinical Results associated with TNFAIP3 x HLA-E x TXNIP x PDL1 x B2M x MANF
Login to view more data
100 Translational Medicine associated with TNFAIP3 x HLA-E x TXNIP x PDL1 x B2M x MANF
Login to view more data
0 Patents (Medical) associated with TNFAIP3 x HLA-E x TXNIP x PDL1 x B2M x MANF
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free